Navigation Links
Soligenix Submits NIAID Contract Proposal for Development of a Thermostable Ricin Vaccine
Date:10/31/2013

AID.  In addition, our organizational structure and experience allows Soligenix to be a valuable strategic partner for NIAID, as well as with the other agencies we currently work with."

The submission of our proposal is non-binding and does not guarantee the award of a NIAID contract.  The contract award will require a favorable technical, scientific and business review by NIAID followed by negotiation of fair and reasonable contract terms.

About RiVax™

RiVax™ is Soligenix's proprietary recombinant subunit vaccine developed to protect against exposure to ricin toxin. With RiVax™, Soligenix is a world leader in the area of ricin toxin vaccine research.

RiVax™ contains a genetically altered version of ricin A chain containing two mutations that inactivate the inherent toxicity of the ricin molecule. The Phase 1A clinical trial was conducted with a formulation of RiVax™ that did not contain an adjuvant. That trial revealed dose dependent seroconversion as well as lack of toxicity of the molecule when administered intramuscularly to human volunteers. The adjuvant-free formulation of  RiVax™ induced toxin neutralizing antibodies that lasted up to 127 days after the third vaccination in several individuals.  To increase the longevity and magnitude of toxin neutralizing antibodies, RiVax™ was formulated with an adjuvant of aluminum salts (known colloquially as Alum) for the Phase 1B clinical trial.  Alum is an adjuvant that is used in many human vaccines, including most vaccines used in infants. In preclinical animal studies, the Alum formulation of RiVax™ induced higher titers and longer lasting antibodies than the adjuvant-free vaccine. 

The development of RiVax™ has been sponsored through a series of overlapping grants from both the NIAID and FDA, which were granted to Soligenix and to UTSW where the vaccine originated. To date, Soligenix and UTSW ha
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
2. Soligenix Reports First Quarter 2012 Financial Results and Highlights Recent Accomplishments
3. Soligenix Reports Second Quarter 2012 Financial Results and Highlights Recent Accomplishments
4. Soligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
5. FDA Grants Soligenix Fast Track Designation for SGX203 for the Treatment of Pediatric Crohns Disease
6. Soligenix Reports Third Quarter 2012 Financial Results and Highlights Recent Accomplishments
7. FDA Grants Soligenix Fast Track Designation for OrbeShield(TM) for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
8. Soligenix Announces Formation of Oral Mucositis Medical Advisory Board
9. Soligenix to Present at 15th Annual BIO CEO & Investor Conference
10. Soligenix Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate SGX942 for the Treatment of Oral Mucositis
11. Soligenix to Present at World Vaccine Congress & Expo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014  Aethlon Medical, Inc. ... devices to address infectious disease, cancer and other ... Research Projects Agency (DARPA) has informed the Company ... proceed with year four of a five-year $5.9 ... September 30, 2011 under DARPA,s Dialysis-Like Therapeutics (DLT) ...
(Date:9/22/2014)... , Sept. 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... quarter and fiscal 2014 ended July 31, 2014 on Monday, ... call to discuss the results at 11:00 AM ET. Participating ... Chairman; Andrew A. Krakauer , President and CEO; ... Craig A. Sheldon , Senior Vice President, CFO and Treasurer; ...
(Date:9/22/2014)... SAN FRANCISCO , Sept. 22, 2014  Sutro ... FierceBiotech as one of 2014,s Fierce 15 ... promising private biotechnology companies in the industry.  ... A-list group of backers as well as industry partners ... developing antibody-drug conjugates and bispecifics," says John Carroll ...
Breaking Medicine Technology:Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 3
... March 22 Cambrex Corporation (NYSE: ... a privately held company that is a leader in ... Wiesbaden, Germany and offers cost effective customized ... pharmaceutical industry, with the ability to utilize its tool ...
... Inc. (OTC Bulletin Board: GOVX), a biotechnology company that is developing and testing innovative HIV/AIDS vaccines, has engaged The Investor Relations Group ("IRG"), ... , ... , ... ...
Cached Medicine Technology:Cambrex Acquires IEP GmbH 2Cambrex Acquires IEP GmbH 3GeoVax Labs Engages The Investor Relations Group 2GeoVax Labs Engages The Investor Relations Group 3GeoVax Labs Engages The Investor Relations Group 4
(Date:9/22/2014)... Alan Mozes HealthDay Reporter ... take note: Many American parents are aware of online physician-rating ... a pediatrician for their children, according to a new national ... than 1,600 parents -- further suggest that negative online ratings ... doctor has been recommended by a neighbor. Conversely, a ...
(Date:9/22/2014)... Asians living in Canada have a higher rate of ... with while people, McMaster researchers have found. , ... Medical Association Journal (CMAJ Open) and may be ... fastest-growing ethnic groups in the country is the more ... comprising about three percent of the population. They include ...
(Date:9/22/2014)... Kessler researchers have published a pilot study showing ... in people with multiple sclerosis (MS). Improvements ... stress, and pain. "Development and effectiveness of ... MS: Description and outcomes" was epublished ahead of ... Journal of MS Care (doi: 10.7224/1537-2073.2013-045). The ...
(Date:9/22/2014)... new prescription devices approved by the U.S. Food and ... with migraine headaches who don,t tolerate migraine medications well, ... the Cefaly -- is designed to prevent migraines, while ... to be used when migraines first start, according to ... for alternative migraine treatments. Because these devices aren,t ingested ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Severe weather can occur ... time. That’s why, as part of National Preparedness Month, Amica ... your family prepare for the unexpected:, , Build ... as nonperishable food and one gallon of water per person per ... Create an evacuation plan that includes pets so your family knows ...
Breaking Medicine News(10 mins):Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 2Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 3Health News:Higher risk of heart disease for South Asians in Canada 2Health News:Noninvasive Devices May Help Migraines, FDA Says 2Health News:Amica Shares Tips for National Preparedness Month 2
... N.J., Feb. 17 Novo Nordisk, a global healthcare ... of Andy Ajello as vice president for National Diabetes ... Executive Team and will report directly to Jerzy Gruhn, ... recently the associate vice president of Diabetes Sales for ...
... Little known language in the economic stimulus ... efforts by nonprofit hospitals - resulting in fewer ... of essential health care services provided to the ... the 11th hour thanks to the efforts of ...
... CryoLife, Inc. (NYSE: CRY ), a,biomaterials, medical ... Food and Drug Administration (FDA) has cleared a new ... The new labeling claim,relates to reducing a component of ... CryoValve SG pulmonary human heart ...
... Year,s Most Common ClaimsBREA, Calif., Feb. 17 Not ... and cuddly. Take ear infections, for example, or skin ... (VPI), the nation,s oldest and largest provider of pet ... to find the year,s most common pet maladies. The ...
... "natural" ingredients should be regarded as a driver for ... 17 According to Kline & Company,s study ... 2008: U.S. and Europe , botanicals consumption is growing ... average growth of 5.4%. The increased use of botanicals ...
... DIEGO, Feb. 17 Tracon Pharmaceuticals, a biotechnology company ... announced today that its three clinical stage cancer therapeutics ... 100th Annual Meeting of the American Association for Cancer ... program targets a unique pathway with the potential for ...
Cached Medicine News:Health News:Novo Nordisk Appoints Andy Ajello as Vice President for National Diabetes Sales, Managed Care and Government Accounts 2Health News:Philanthropic Fundraising Activities in Stimulus Bill Preserved Thanks to the Efforts of the Association for Healthcare Philanthropy 2Health News:FDA Clears New Immune Response Claim for the CryoValve(R) SG Pulmonary Human Heart Valve 2Health News:FDA Clears New Immune Response Claim for the CryoValve(R) SG Pulmonary Human Heart Valve 3Health News:Sick as a Dog: Pets' Top Medical Conditions of 2008 2Health News:Sick as a Dog: Pets' Top Medical Conditions of 2008 3Health News:Desire for Performance Coupled With Natural Ingredients Boosts Botanical Actives Consumption in Personal Care 2Health News:Desire for Performance Coupled With Natural Ingredients Boosts Botanical Actives Consumption in Personal Care 3Health News:Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009 2Health News:Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: